Научно-Исследовательский Институт Проблем Биологической Безопасности

COVID-19 DOMESTIC VACCINE DEVELOPED AT RIBSP IS OFFICIALLY APPROVED BY THE WORLD HEALTH ORGANIZATION (WHO) TO CLINICAL TRIALS

The World Health Organization (WHO) has officially included our domestic inactivated vaccine, developed by scientists of our Institute, into the list of vaccines approved for clinical trials.

Kazakhstan vaccine with inactivated virus is in phase 1/2 of clinical trial.

The list of vaccines officially approved for clinical trials by WHO also includes 33 vaccines developed by companies or research institutes from 19 countries of the world, such as Great Britain, China, Russia, USA, Germany, Japan, India, South Korea, Belgium, Sweden, Singapore, Italy, Australia, Taiwan, Cuba, France, Austria, and Canada.

Since September this year clinical trials of the vaccine will begin on 244 volunteers, 44 of whom will receive the vaccine in the first phase of clinical trials, the rest – in the second.

Draft landscape of COVID-19 candidate vaccines